Christopher Raymond
Stock Analyst at Piper Sandler
(0)
# 4168
Out of 5,218 analysts
137
Total ratings
44.44%
Success rate
-5.85%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Q32 Bio | Maintains: Overweight | 85 20 | 3.69 | 442.01% | 2 | Dec 11, 2024 | |
Aclaris Therapeutics | Upgrades: Overweight | 3 13 | 3.23 | 302.48% | 2 | Nov 18, 2024 | |
Karyopharm Therapeut... | Maintains: Overweight | 4 5 | 0.7 | 614.29% | 4 | Nov 6, 2024 | |
Regeneron Pharmaceut... | Maintains: Overweight | 1242 1195 | 730.7 | 63.54% | 6 | Nov 1, 2024 | |
Biohaven | Maintains: Overweight | 66 76 | 38.47 | 97.56% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 107 122 | 66.03 | 84.76% | 11 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 10 | 0.81 | 1134.57% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 196 209 | 173.5 | 20.46% | 10 | Aug 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 33 | 14.96 | 120.59% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 500 535 | 463.5 | 15.43% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 335 313 | 150.04 | 108.61% | 14 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 7 | 2.06 | 239.81% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 15 | 5.21 | 187.91% | 6 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 78 104 | 93.28 | 11.49% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 42 | 7.15 | 487.41% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 21 | 1.45 | 1348.28% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 27 2 | 0.45 | 233.33% | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 18 23 | n/a | n/a | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 135 130 | 45.88 | 183.35% | 4 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 4 | n/a | n/a | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22 | 8.22 | 167.64% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 2 4 | 1.84 | 117.39% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 17 | n/a | n/a | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 25 | 6.12 | 308.5% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 293 288 | 270.45 | 6.49% | 11 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 41 | 39.09 | 4.89% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 3 1 | n/a | n/a | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 2 | n/a | n/a | 3 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 28 | 57.26 | -51.1% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 12 | n/a | n/a | 2 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 56 28 | n/a | n/a | 4 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 146 180 | n/a | n/a | 2 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 86.68 | -53.85% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 90 | 4.93 | 1725.56% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | n/a | n/a | n/a | 3 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 60 35 | n/a | n/a | 1 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | n/a | n/a | 1 | Apr 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 96 | 2.29 | 4092.14% | 2 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 170 | n/a | n/a | 1 | Oct 23, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Neutral | 133 | n/a | n/a | 2 | Oct 23, 2017 |